NSCLC中SSTR2和SSTR5的表达与微血管密度及预后的相关性

  目的  检测非小细胞肺癌(non-small cell lung cancer, NSCLC)组织生长抑素受体(somastostatin receptor, SSTR)亚型SSTR2、SSTR5的表达, 探讨其与肿瘤新生血管程度的关系及对临床预后判断的价值。  方法  免疫组织化学S-P法检测54例NSCLC组织标本和21例肺癌旁组织标本中SSTR2和SSTR5蛋白表达情况; CD34抗体标记血管内皮细胞, 计算MVD。  结果  在NSCLC组织中, SSTR2和SSTR5的阳性表达率分别51.9%(28/54)和55.6%(30/54), 与肺癌旁组织中的表达率14.3%(3/21)和19.0%(4/21)相比, 差异有统计学意义(P < 0.05)。SSTR2、SSTR5表达与NSCLC的TNM分期密切相关(P < 0.05), 与年龄、性别、吸烟与否、肿瘤组织类型、分化程度、肿瘤大小和淋巴结转移均无明显相关(P > 0.05)。本研究中, 有淋巴结转移者MVD高于无淋巴结转移者(P < 0.05)、中晚期患者(Ⅲ~Ⅳ期)MVD高于早期患者(Ⅰ~Ⅱ期)(P < 0.05);不同年龄、性别、吸烟与否、肿瘤组织类型、分化程度和肿瘤大小之间MVD无显著性差异(P > 0.05)。SSTR2、SSTR5表达阳性者3年生存率分别为70.4%、66.1%;表达阴性者3年生存率分别为35.3%、37.3%。SSTR2、SSTR5的表达与MVD值呈负相关(P < 0.05)。  结论  NSCLC中新生血管的程度与其发生、发展和转移密切相关。SSTR2、SSTR5阳性表达者肿瘤新生血管程度较低, 预后较好。 

Expression of SSTR2 and SSTR5 in Non-small Cell Lung Cancer and Its Correlation with Microvessel Density

  Objective  To investigate the expression of SSTR2 and SSTR5 in non-small cell lung cancer, and explore their relationship with angiogenesis, clinical parameters, and prognosis.  Methods  Immunohistochemical staining was used to detect the expression of SSTR2 and SSTR5 proteins in 54 cases of NSCLC and 21 tumor-adjacent normal lung tissues.The microvessels were immuno-histochemically labeled with anti-CD34 antibody to assess microvessel density.  Results  In the NSCLC tissues, the expression rates of SSTR2 and SSTR5 proteins were 51.9%(28/54)and 55.6%(30/54), respectively.Meanwhile, in the tumor-adjacent normal lung tissues, the positive rates of SSTR2 and SSTR5 were 14.3%(3/21)and 19.0%(4/21), respectively.The difference was statistically significant (P < 0.05).The expression of SSTR2 and SSTR5 proteins was closely related to TNM stage(P < 0.05), but insignificantly related to patient age, sex, smoking history, pathological type, differentiation grade, tumor size, and lymph node metastasis(P > 0.05).Increased MVD was correlated to lymph node metastasis and advanced stage(Ⅲ~Ⅳ)(P < 0.05), but uncorrelated to patient age, sex, smoking history, pathological type, differentiation grade, and tumor size(P > 0.05).The three-year survival rates were 70.4%and 66.1%in patients who are positive of SSTR2 and SSTR5, respectively, and 35.3%and 37.3%in those who are negative of the two proteins.There was a negative correlation between MVD with the expression of SSTR2 and SSTR5 in the NSCLC tissues(P < 0.05).  Conclusion  The MVD increased along with the progression of NSCLC.The expression of SSTR2 and SSTR5 proteins was negatively related to angiogenesis and may suggest a good prognosis.